Strategic Focus Small biotech with specialized NGS analytics and cloud options; target potential buyers in labs needing cost-effective genomic data interpretation platforms, including metagenomics, offering scalable deployment to support personalized medicine initiatives.

Product Maturity Longstanding RTG Core platform with iterative releases since 2016–2021 indicates a mature, validated suite; sales approach can emphasize proven reliability and the ability to install on client compute environments or provide cloud access to reduce time to value.

Partnerships Potential Historical collaboration with TOMA Biosciences on clinical-grade tools signals openness to co-development and strategic partnerships; pursue opportunities with oncology labs and liquid biopsy workflows seeking robust analysis pipelines.

Financial Position Revenue under one million with $8 million in funding suggests a lean vendor capable of focused, high-impact engagements; emphasize flexible pricing, pilot programs, and quick ROI to attract budget-constrained customers.

Market Fit Competitively situated among agile genomics analytics vendors; position RTG Core as a cost-effective alternative to larger platforms for NGS and metagenomics, highlighting ease of deployment, cloud access, and tailored support for life sciences teams.